COMBANTRIN ® Pirantel Pamoato

COMBANTRIN ® is a drug based on Piratel Pamoate

THERAPEUTIC GROUP: Anthelmintic

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications COMBANTRIN ® Pirantel Pamoato

COMBANTRIN ® is indicated for the treatment of parasitic diseases sustained by pinworms, roundworms and hookworms.

COMBANTRIN ® Pirantel Pamoate action mechanism

COMBANTRIN ® is an antiparasitic drug based on Pirantel Pamoate, salt of pamoic acid, which allows a rapid action at the intestinal level following oral intake, reducing its absorption and potential systemic effects to a minimum.

Its therapeutic activity, particularly effective against intestinal parasites, is realized through the inhibitory action against the nicotinic receptor of the neuromuscular plaque of the parasite, with consequent paralysis.

In this way the parasite loses its invasive abilities towards the gastro-enteric mucosa, thus being eliminated directly through the faeces.

The small amount of drug absorbed is eliminated mainly through the urine, partly unchanged and partly in the form of inactive metabolites.

Studies carried out and clinical efficacy

EFFECTIVENESS OF METRONIDAZOL-PIRANTEL IN THE TREATMENT OF THE GARDEN

Parasitol Int. 2011 Jan; 60 (1): 54-8.

Study evaluating the efficacy and safety of the Metronidazole - Pirantel Pamoate therapeutic combination in the treatment of Giardia Lamblia, demonstrating an excellent cytotoxic activity enhanced by the synergistic action.

THE PIRANTEL IN THE CONTROL OF THE DIFFUSION OF PARASITOSIS FROM NEMATODI

Trans R Soc Trop Med Hyg. 2002 Nov-Dec; 96 (6): 685-90.

Clinical trial demonstrating the effectiveness of Pirantel in controlling the spread of intestinal nematodes in young patients living in the Sub-Saharan region where the presence of such parasites is endemic and particularly widespread.

MOLECULAR MECHANISM OF THE PIRANTEL

Neuropharmacology. 2001 Aug; 41 (2): 238-45.

Interesting cellular study that seeks to characterize the molecular activity of Pirantel, demonstrating how this is particularly effective against nicotinic nematode receptors, while it has modest biological activity against nicotinic receptors of human muscle cells, thus limiting the potential side effects .

Method of use and dosage

COMBANTRIN ®

Pirantel Pamoate 720 mg chewable tablets equal to 250 mg of Pirantel;

Oral suspension at 5% of Pirantel Pamoate.

The COMBANTRIN ® based therapy should be defined by your doctor based on the clinical picture present and the physiopathological characteristics of the patient with particular reference to body weight, from the moment in which average dosages of 10 mg of active principle per Kg of are generally suggested. body weight.

It is recommended to take the drug in a single daily dose, regardless of meals.

Warnings COMBANTRIN ® Pirantel Pamoato

Before taking COMBANTRIN ® it would be advisable for the patient to undergo a careful medical examination in order to clarify the characteristics of the infestation and above all the possible risk of transmission to the partners.

For this reason, parallel to the drug therapy it would be advisable to pay particular attention also to the compliance with specific hygienic rules useful for limiting the spread of the parasite.

Use of the drug should be done with particular caution in patients with liver and kidney disease.

PREGNANCY AND BREASTFEEDING

The absence of clinical trials able to fully characterize the safety profile of the drug for fetal health greatly limits the use of COMBANTRIN ® during pregnancy and in the subsequent period of breastfeeding.

Interactions

Drug interactions worthy of clinical note are currently unknown.

Contraindications COMBANTRIN ® Pirantel Pamoate

The use of COMBANTRIN ® is contraindicated in case of hypersensitivity to the active ingredient or to one of its excipients.

Undesirable effects - Side effects

The use of COMBANTRIN ® is generally safe although sometimes associated with the appearance of pathologically transient manifestations such as anorexia, diarrhea, vomiting, abdominal cramps, increased transaminases, headache, dizziness and drowsiness.

Rare are the cases of hypersensitivity to the drug characterized by ingravescent dermatological manifestations or even more significant clinical pictures.